通过辅助剂加载的冷冲击瘤细胞来加强癌症疫苗接种
Mo Chen1, Huangjuan Li2, Jing Zang3
1Department of Pharmaceutical Sciences, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China; Department of Pharmaceutics, China Pharmaceutical University, Nanjing, Jiangsu province, 210009, China.
Biomaterials
|September 23, 2023
概括
一种新型的癌症疫苗使用液治疗瘤细胞 (LNT细胞) 作为抗原和辅助剂的输送载体. 与传统方法相比,这种方法提高了黑色素瘤模型中的抗瘤反应和存活率.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 生物技术是生物技术.
背景情况:
- 癌症疫苗显示出免疫治疗的前景.
- 目前的全细胞疫苗在抗原/辅助剂输送方面存在局限性.
研究的目的:
- 使用液处理 (LNT) 细胞开发一种简单有效的癌症疫苗.
- 评估LNT细胞作为增强抗瘤免疫力的抗原和辅助载体的有效性.
主要方法:
- 通过在液中对活瘤细胞进行冲击,开发出LNT细胞.
- 用辅助物伊米基莫德 (R837) 装载的LNT细胞.
- 评估了抗原呈现细胞 (APC) 的共吸收和体内保留.
主要成果:
- 瘤细胞有效地传递瘤抗原和辅助剂.
- 在体内长时间保持抗原和辅助剂.
- 在黑色素瘤小鼠模型中证明了体内增强的抗瘤反应和增强的存活率.
结论:
- 装有辅助剂的LNT细胞代表了癌症免疫治疗的有前途的战略.
- 这种新型疫苗设计改进了传统的全细胞疫苗.
相关概念视频
Cancer Vaccines
396
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
396
Tumor Immunotherapy
551
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
551
Vaccinations
44.6K
Overview
44.6K


